These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 29066370)

  • 21. Effects of Age and Sex of Response to Ursodeoxycholic Acid and Transplant-free Survival in Patients With Primary Biliary Cholangitis.
    Cheung AC; Lammers WJ; Murillo Perez CF; van Buuren HR; Gulamhusein A; Trivedi PJ; Lazaridis KN; Ponsioen CY; Floreani A; Hirschfield GM; Corpechot C; Mayo MJ; Invernizzi P; Battezzati PM; Parés A; Nevens F; Thorburn D; Mason AL; Carbone M; Kowdley KV; Bruns T; Dalekos GN; Gatselis NK; Verhelst X; Lindor KD; Lleo A; Poupon R; Janssen HLA; Hansen BE;
    Clin Gastroenterol Hepatol; 2019 Sep; 17(10):2076-2084.e2. PubMed ID: 30616022
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development and Validation of a Scoring System to Predict Outcomes of Patients With Primary Biliary Cirrhosis Receiving Ursodeoxycholic Acid Therapy.
    Lammers WJ; Hirschfield GM; Corpechot C; Nevens F; Lindor KD; Janssen HL; Floreani A; Ponsioen CY; Mayo MJ; Invernizzi P; Battezzati PM; Parés A; Burroughs AK; Mason AL; Kowdley KV; Kumagi T; Harms MH; Trivedi PJ; Poupon R; Cheung A; Lleo A; Caballeria L; Hansen BE; van Buuren HR;
    Gastroenterology; 2015 Dec; 149(7):1804-1812.e4. PubMed ID: 26261009
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Natural History of Primary Biliary Cholangitis in the Ursodeoxycholic Acid Era: Role of Scoring Systems.
    Goel A; Kim WR
    Clin Liver Dis; 2018 Aug; 22(3):563-578. PubMed ID: 30259853
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Utilization of the Mayo risk score in patients with primary biliary cirrhosis receiving ursodeoxycholic acid.
    Angulo P; Lindor KD; Therneau TM; Jorgensen RA; Malinchoc M; Kamath PS; Dickson ER
    Liver; 1999 Apr; 19(2):115-21. PubMed ID: 10220741
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognosis of 732 ursodeoxycholic acid-treated patients with primary biliary cholangitis: A single center follow-up study from China.
    Chen S; Duan W; Li M; Li S; Lv T; Tian Q; Wang Q; Wu X; Zhao X; Wang X; Wang Y; Kong Y; Ma H; Ou X; You H; Jia J
    J Gastroenterol Hepatol; 2019 Jul; 34(7):1236-1241. PubMed ID: 30365184
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Epidemiology of primary biliary cirrhosis in Victoria, Australia: high prevalence in migrant populations.
    Sood S; Gow PJ; Christie JM; Angus PW
    Gastroenterology; 2004 Aug; 127(2):470-5. PubMed ID: 15300579
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pruritus Is Common and Undertreated in Patients With Primary Biliary Cholangitis in the United Kingdom.
    Hegade VS; Mells GF; Fisher H; Kendrick S; DiBello J; Gilchrist K; Alexander GJ; Hirschfield GM; Sandford RN; Jones DEJ;
    Clin Gastroenterol Hepatol; 2019 Jun; 17(7):1379-1387.e3. PubMed ID: 30557739
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Research progress on risk factors for poor response of ursodeoxycholic acid in primary biliary cholangitis].
    Yuan Z; Jia G; Han Y
    Zhonghua Gan Zang Bing Za Zhi; 2019 Jan; 27(1):73-76. PubMed ID: 30685931
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Transcutaneous Neuromodulation improved inflammation and sympathovagal ratio in patients with primary biliary ssscholangitis and inadequate response to Ursodeoxycholic acid: a pilot study.
    Yang H; Yang H; Wang L; Shi H; Liu B; Lin X; Chang Q; Chen JDZ; Duan Z
    BMC Complement Med Ther; 2020 Aug; 20(1):242. PubMed ID: 32738911
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of fenofibrate add-on therapy for patients with primary biliary cholangitis and a suboptimal response to UDCA.
    Duan W; Ou X; Wang X; Wang Y; Zhao X; Wang Q; Wu X; Zhang W; Ma H; You H; Jia J
    Rev Esp Enferm Dig; 2018 Sep; 110(9):557-563. PubMed ID: 29739227
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association between serum soluble CD14 and IL-8 levels and clinical outcome in primary biliary cholangitis.
    Umemura T; Sekiguchi T; Joshita S; Yamazaki T; Fujimori N; Shibata S; Ichikawa Y; Komatsu M; Matsumoto A; Shums Z; Norman GL; Tanaka E; Ota M
    Liver Int; 2017 Jun; 37(6):897-905. PubMed ID: 27860118
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Twenty-Year Comparative Analysis of Patients With Autoimmune Liver Diseases on Transplant Waitlists.
    Webb GJ; Rana A; Hodson J; Akhtar MZ; Ferguson JW; Neuberger JM; Vierling JM; Hirschfield GM
    Clin Gastroenterol Hepatol; 2018 Feb; 16(2):278-287.e7. PubMed ID: 28993258
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of S-adenosyl-L-methionine on liver biochemistry and quality of life in patients with primary biliary cholangitis treated with ursodeoxycholic acid. A prospective, open label pilot study.
    Wunsch E; Raszeja-Wyszomirska J; Barbier O; Milkiewicz M; Krawczyk M; Milkiewicz P
    J Gastrointestin Liver Dis; 2018 Sep; 27(3):273-279. PubMed ID: 30240471
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Factors Associated With Progression and Outcomes of Early Stage Primary Biliary Cholangitis.
    Gatselis NK; Goet JC; Zachou K; Lammers WJ; Janssen HLA; Hirschfield G; Corpechot C; Lindor KD; Invernizzi P; Mayo MJ; Battezzati PM; Floreani A; Pares A; Lygoura V; Nevens F; Mason AL; Kowdley KV; Ponsioen CY; Bruns T; Thorburn D; Verhelst X; Harms MH; van Buuren HR; Hansen BE; Dalekos GN;
    Clin Gastroenterol Hepatol; 2020 Mar; 18(3):684-692.e6. PubMed ID: 31419573
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid.
    Kuiper EM; Hansen BE; de Vries RA; den Ouden-Muller JW; van Ditzhuijsen TJ; Haagsma EB; Houben MH; Witteman BJ; van Erpecum KJ; van Buuren HR;
    Gastroenterology; 2009 Apr; 136(4):1281-7. PubMed ID: 19208346
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Major Hepatic Complications in Ursodeoxycholic Acid-Treated Patients With Primary Biliary Cholangitis: Risk Factors and Time Trends in Incidence and Outcome.
    Harms MH; Lammers WJ; Thorburn D; Corpechot C; Invernizzi P; Janssen HLA; Battezzati PM; Nevens F; Lindor KD; Floreani A; Ponsioen CY; Mayo MJ; Dalekos GN; Bruns T; Parés A; Mason AL; Verhelst X; Kowdley KV; Goet JC; Hirschfield GM; Hansen BE; van Buuren HR;
    Am J Gastroenterol; 2018 Feb; 113(2):254-264. PubMed ID: 29231188
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of a Latitude Gradient in the Prevalence of Primary Biliary Cholangitis.
    French J; Simpson-Yap S; van der Mei I; Ng J; Angus P; Gow PJ
    Clin Transl Gastroenterol; 2021 May; 12(5):e00357. PubMed ID: 34003806
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The natural history of primary biliary cirrhosis.
    Imam MH; Lindor KD
    Semin Liver Dis; 2014 Aug; 34(3):329-33. PubMed ID: 25057955
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Influence factors and a predictive scoring model for measuring the biochemical response of primary biliary cholangitis to ursodeoxycholic acid treatment.
    Chen J; Xue D; Gao F; Tao L; Li Y; Zhang Q; Wang R; Sun L; Yang X; Liu Y; Zhu B; Niu S; Wang X
    Eur J Gastroenterol Hepatol; 2018 Nov; 30(11):1352-1360. PubMed ID: 29889683
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Optimising risk stratification in primary biliary cirrhosis: AST/platelet ratio index predicts outcome independent of ursodeoxycholic acid response.
    Trivedi PJ; Bruns T; Cheung A; Li KK; Kittler C; Kumagi T; Shah H; Corbett C; Al-Harthy N; Acarsu U; Coltescu C; Tripathi D; Stallmach A; Neuberger J; Janssen HL; Hirschfield GM
    J Hepatol; 2014 Jun; 60(6):1249-58. PubMed ID: 24548531
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.